Susquehanna International Group
PTGX icon

Susquehanna International Group’s Protagonist Therapeutics PTGX Stock Holding History

Susquehanna International Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7M Buy
167,576
+155,814
+1,325% +$13.8M ﹤0.01% 2380
2025
Q4 		$1.03M Sell
11,762
-51,426
-81% -$4.21M ﹤0.01% 7130
2025
Q3 		$4.2M Sell
63,188
-8,053
-11% -$458K ﹤0.01% 4373
2025
Q2 		$3.94M Sell
71,241
-120,998
-63% -$5.81M ﹤0.01% 4419
2025
Q1 		$9.3M Buy
192,239
+122,302
+175% +$5.12M ﹤0.01% 2623
2024
Q4 		$2.7M Buy
69,937
+29,580
+73% +$1.29M ﹤0.01% 4673
2024
Q3 		$1.82M Sell
40,357
-315,229
-89% -$12.7M ﹤0.01% 5454
2024
Q2 		$12.3M Buy
355,586
+283,768
+395% +$8.31M ﹤0.01% 2231
2024
Q1 		$2.08M Sell
71,818
-37,865
-35% -$1.03M ﹤0.01% 5247
2023
Q4 		$2.52M Buy
109,683
+52,438
+92% +$917K ﹤0.01% 4897
2023
Q3 		$955K Buy
57,245
+41,281
+259% +$801K ﹤0.01% 6729
2023
Q2 		$441K Sell
15,964
-108,120
-87% -$2.71M ﹤0.01% 8597
2023
Q1 		$2.85M Buy
124,084
+57,053
+85% +$958K ﹤0.01% 4431
2022
Q4 		$731K Sell
67,031
-79,457
-54% -$670K ﹤0.01% 6904
2022
Q3 		$1.24M Buy
146,488
+81,328
+125% +$770K ﹤0.01% 6089
2022
Q2 		$516K Buy
65,160
+14,406
+28% +$174K ﹤0.01% 8174
2022
Q1 		$1.2M Sell
50,754
-245,659
-83% -$6.92M ﹤0.01% 6649
2021
Q4 		$10.1M Buy
296,413
+29,030
+11% +$918K ﹤0.01% 2692
2021
Q3 		$4.74M Buy
267,383
+246,050
+1,153% +$10.5M ﹤0.01% 4047
2021
Q2 		$957K Sell
21,333
-12,801
-38% -$423K ﹤0.01% 7897
2021
Q1 		$884K Buy
34,134
+13,781
+68% +$349K ﹤0.01% 8052
2020
Q4 		$410K Buy
20,353
+9,133
+81% +$197K ﹤0.01% 8687
2020
Q3 		$219K Buy
+11,220
New +$211K ﹤0.01% 9313
2019
Q2 		– Sell
-47,788
Closed -$601K – 10710
2019
Q1 		$601K Buy
47,788
+32,580
+214% +$288K ﹤0.01% 5928
2018
Q4 		$102K Buy
+15,208
New +$121K ﹤0.01% 8213

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Susquehanna International Group's PTGX Position: Q1 2026 in Review

Susquehanna International Group increased its Protagonist Therapeutics (PTGX) stake by 1,325% in Q1 2026, buying an estimated $13.8M and bringing the position to 167,576 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Susquehanna International Group first reported a position in PTGX in Q4 2018 and has held it in 25 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Susquehanna International Group held 167,576 shares of Protagonist Therapeutics worth $17.7M as of Q1 2026.
  • Susquehanna International Group bought 155,814 Protagonist Therapeutics shares in Q1 2026, an estimated $13.8M.
  • Protagonist Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2380 holding.
  • Susquehanna International Group first reported a position in Protagonist Therapeutics in Q4 2018 and has held it in 25 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.